翰宇药业与博瑞医药强强联合，多肽创新药出海逻辑再强化

Core Viewpoint - Shenzhen Hanyu Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Borui Biopharmaceuticals to provide stable and high-quality peptide raw material supply for Borui's metabolic pipeline, particularly oral peptide new drugs, leveraging Hanyu's FDA and EMA certified production base [1] Group 1: Company Overview - Hanyu Pharmaceutical has 27 years of experience in the peptide drug field, possessing a complete integrated platform from raw materials to formulations [1] - The company has established an international quality system compliant with FDA, EMA, and NMPA standards, and has extensive experience in drug registration and application in global markets [1] - Borui Biopharmaceuticals focuses on innovative drug development in the metabolic and respiratory disease sectors, with a rich pipeline of innovative drug products [1] Group 2: Strategic Cooperation - The partnership aims to create a long-term stable strategic relationship to support the global industrialization of Borui's innovative drugs [1] - The collaboration is expected to enhance the high-quality international development of China's peptide drug industry through resource complementarity and collaborative innovation between the two companies [1]